Summary

Anti-Venom Market Trends & Summary

Anti-Venom market is expected to reach US$ 2.07 billion by 2033 from US$ 1.18 billion in 2024, with a CAGR of 6.50% from 2025 to 2033. Increasing rates of snake bites and scorpion stings, the introduction of beneficial government programs, and continuous industry advancements are some of the major drivers propelling the market's expansion.

The report Anti-venom Market & Forecast covers by Type (Polyvalent and Monovalent), Animal Type (Wheat Snake, Scorpion, Spider, and Others), End User (Clinics, Hospitals, Ambulatory Surgical Centers, and Others), Region and Company Analysis 2025-2033.


Anti-Venom Industry Overview

In order to tackle poisonous snakebites, bug stings, and other venom-related medical situations, the global anti-venom industry is essential. Specialized biological products called anti-venoms are used to counteract the harmful effects of venom from a variety of species, such as marine animals, snakes, scorpions, and spiders. The need for efficient anti-venoms is vital since snakebites are one of the main causes of death and illness in many poor nations, particularly in areas like sub-Saharan Africa, South Asia, and portions of Latin America. The growing amount of venomous animal bites and stings, increased public awareness of these dangers, and expanding healthcare facilities in high-risk areas are the main factors propelling the market. To lessen the health risk presented by poisonous bites, governments and international health organizations are also concentrating on financing the manufacturing and distribution of anti-venom.

The manufacturing of anti-venom serum is mostly dependent on the collection of venom from different species, and the anti-venom sector is defined by a small number of big manufacturers. High production costs, a shortage of venomous species for serum production, and the requirement for comprehensive clinical testing are some of the industry's obstacles. Additionally, logistical challenges frequently arise during anti-venom distribution, especially in rural and isolated places. Global access to these life-saving medicines is anticipated to improve as a result of biotechnology advancements and the creation of more potent and reasonably priced anti-venoms. International health initiatives that aim to lessen the impact of venomous bites and stings worldwide are supporting the expansion of the anti-venom market.

The World Health Organization (WHO) estimates that every year, about 5.4 million people are bitten by snakes. Moreover, snake bites cause between 81,410 and 137,880 deaths worldwide each year. After the COVID-19 pandemic was declared in 2020, an estimated 2.7 million cases of snakebite envenoming (SBE) resulted in over 100,000 fatalities and 400,000 long-term impairments in the poorest and most rural communities in Asia, Africa, and Latin America, according to a study published in the British Medical Journal in October 2021.


Growth Drivers for the Anti-Venom Market

Developments in Biotechnology

The creation of more potent and precise anti-venoms has been greatly aided by developments in biotechnology. Anti-venoms based on monoclonal antibodies have become more effective and safer, providing quicker and more accurate treatments. There are now more anti-venoms accessible, targeting different venom types and increasing the likelihood of effective outcomes thanks to new research in venom immunotherapy and recombinant technologies. These developments have improved the general accessibility and availability of anti-venom medications while assisting in reducing production costs. For example, researchers from the University of Sydney and the Liverpool School of Tropical Medicine found in July 2024 that heparin, a blood thinner, can also be employed as an inexpensive counteragent for cobra venom. Nearly 100,000 people are killed by snakes each year, and heparin can be used as a cheap counteragent against cobra venom.


Support from the Government and Healthcare

The market for anti-venom is mostly driven by government initiatives and rising spending in the healthcare system. In order to ensure accessibility, especially in rural and disadvantaged areas, several governments in endemic regions set aside money for the purchase and distribution of anti-venoms. NGOs and public health groups also collaborate to increase access to and knowledge about life-saving therapies. This teamwork is essential to lowering venomous bite death rates and improving emergency medical responses in impacted areas. For example, the Union Health Secretary of India unveiled the National Action Plan for Prevention and Control of Snakebite Envenoming (NAP-SE) in March 2024. In order to reduce the number of snakebite deaths by half by 2030, NAPSE provides the Indian states with a thorough framework for developing their action plans for managing, preventing, and controlling snakebites utilizing the "One Health" concept. The activities planned under the human, wildlife, tribal, and animal health components will be carried out by interested stakeholders at all levels.


Growing Rates of Venomous Stings and Snakebite

One major factor propelling the growth of the anti-venom market is the rising incidence of snakebites and venomous bug stings, particularly in tropical and subtropical areas. The number of human contacts with poisonous animals has increased due to factors like urbanization, deforestation, and climate change. The need for efficient anti-venoms to reduce fatalities and long-term health issues has increased as a result of the rise in cases and a greater understanding of the significance of prompt treatment. The World Health Organization (WHO) states that snakebite is a neglected public health issue in many tropical and subtropical countries. The majority of these occur in Asia, Africa, and Latin America. Up to 2 million people in Asia are bitten by snakes annually, and between 435,000 and 580,000 snake bites in Africa result in medically necessary treatment.


Challenges in the Anti-Venom Market

Limited Venom Availability

One of the biggest problems facing the anti-venom market is the limited availability of venom. Access to venomous species is necessary for venom extraction for anti-venom manufacture, however these species are sometimes hard to find and geographically limited. It can be difficult to create anti-venoms for uncommon or location-specific bites, for instance, because some poisonous snakes, scorpions, or marine species are only present in particular areas. Because of this, there are shortages of supplies, especially in isolated or underdeveloped locations where these species are common. Attempts to guarantee a consistent supply of anti-venoms are further complicated by the fact that the collection and extraction procedure itself can be difficult and time-consuming. Meeting the need for life-saving medicines worldwide is made more difficult by the shortage of certain venoms, especially in high-risk areas.


Cold Chain and Distribution Challenges

One of the biggest obstacles in the anti-venom market is the cold chain and distribution issues. The worldwide distribution of anti-venoms is complicated by the need for rigorous temperature control during storage and transit in order to preserve their effectiveness. Maintaining the cold chain is frequently challenging in locations with inadequate infrastructure, particularly in rural or isolated parts of developing nations. Treatments are delayed as a result of these logistical problems because antivenoms might not be available when needed or because improperly stored products might deteriorate. Furthermore, because anti-venoms that are expired or inadequately maintained must be thrown away, the high expenses and restricted availability of refrigerated facilities in these locations may lead to waste. This limits access to life-saving medicines in high-risk areas and lessens the effectiveness of anti-venom distribution.


Anti-Venom Market Data and Statistics

• The WHO has started a plan to stop and manage snakebite envenomation, a tropical illness that kills millions of people every year.

• Around the world, snakebites are a serious problem. About 2 million people in Asia be bitten by snakes every year, while between 435,000 and 580,000 people in Africa are thought to need treatment for snakebite each year.

• In India alone, there are 2.8 million snakebite cases annually, resulting in 46,900 fatalities.

• According to a National Center for Biotechnology Information (NCBI) report, the number of snakebite hospital admissions in 2020 was 25% lower than in prior years at a tertiary hospital in Bangladesh that houses a snakebite treatment unit.

• In 2021, ten Latin American laboratories—including Instituto Butantan and Instituto Nacional de Salud—reported a decrease in the output of snake antivenom.

• National Health Expenditures (NHE) in the United States are expected to reach USD 6,192.5 billion in 2028, with an average annual percent change of 5.2%, according to the Centers for Medicare & Medicaid Services (CMS).

• By 2028, the per capita expenditure is predicted to reach USD 17,611, suggesting that this increase in NHE would likely lead to profitable business prospects.


Anti-Venom Market Overview by Regions

By countries, the global Anti-Venom market is divided into United States, Canada, France, Germany, Italy, Spain, United Kingdom, Belgium, Netherland, Turkey, China, Japan, India, South Korea, Thailand, Malaysia, Indonesia, Australia, New Zealand, Brazil, Mexico, Argentina, Saudi Arabia, UAE, and South Africa.


United States Anti-Venom Market

The necessity for efficient remedies for poisonous snakebite, bug sting, and other venom-related situations is driving the sizeable anti-venom market in the United States. Anti-venom is widely available in hospitals and emergency rooms across the United States, which boasts a sophisticated healthcare system. This is especially true in areas like the Southwest and Southeast that are prone to snakebite incidents. Strong medical research, regulatory monitoring, and advancements in the treatment of poisonous species all boost the industry. The high cost of producing antivenoms, the scarcity of some venoms for extraction, and the requirement for cold chain management throughout distribution are obstacles, though. The market is also impacted by the growing number of animal bites and knowledge of poisonous species, which call for the constant supply of anti-venom products for prompt, efficient treatment.


Germany Anti-Venom Market

Driven by the nation's sophisticated research in venom-related treatments and well-established medical infrastructure, Germany's anti-venom industry is an essential part of its healthcare system. Anti-venoms are nevertheless needed, especially to treat attacks from native venomous species like the European adder, even though venomous animal bites like snakebites and insect stings are less frequent in Germany than in tropical areas. Germany's robust regulatory environment, which guarantees the safety and effectiveness of anti-venoms, supports the market. Germany also contributes to the European market by manufacturing and exporting antivenoms. However, issues including exorbitant manufacturing costs, the requirement for cold chain logistics, and restricted access to particular venoms could impact supply. Both domestic demand and contributions to international anti-venom supply networks sustain the business.


India Anti-Venom Market

Due to the high frequency of poisonous snakebite, scorpion sting, and other venom-related crises, India has one of the largest anti-venom markets in the world. The increasing demand for anti-venom treatments, especially in rural and underserved areas, is a result of India's wide variety of venomous animals, which include cobras, vipers, and kraits. Health organizations and government programs aimed at increasing access to life-saving medicines in high-risk areas are supporting the industry. However, obstacles include the expensive cost of anti-venoms, the inability to maintain the cold chain for distribution, and the lack of adequate healthcare infrastructure in rural areas. Because there aren't many venomous species available for venom extraction, the market also has supply problems. With better distribution networks and more awareness, India's anti-venom business is still expanding in spite of these obstacles.

In Around 5.4 million snake bites happen year, leading to up to 2.7 million envenomation’s (poisonings from snake bites) and between 81,000 and 138,000 fatalities, according to the WHO's May 2021 update. Additionally, it frequently results in around three times as many amputations and other long-term impairments. The report "Accidental Deaths & Farm Suicides in India," released in August 2022, states that 10,450 snakebite instances were documented in India in 2021, resulting in 10,382 fatalities and 64 injuries. In 2021, Madhya Pradesh led the way in snake bite deaths (2,732), followed by Odisha (1,019), Chhattisgarh (909), and Uttar Pradesh (844), according to the data. Therefore, it is anticipated that the rising number of snake bites will raise demand for anti-venom treatments, which will accelerate market expansion.


United Arab Emirates Anti-Venom Market

The United Arab Emirates' anti-venom market is expanding due to the nation's high level of wealth, contemporary healthcare system, and growing awareness of the dangers of venomous bites, especially from snakes, scorpions, and other desert-dwelling animals. Due to the UAE's geographic location in an area with many poisonous species, including scorpions and the Arabian horned viper, there is a need for anti-venoms among both local and foreign visitors. The government has made improvements in healthcare a top priority, making sure that medical facilities like hospitals have anti-venoms and other therapies. The high expense of importing anti-venoms and the requirement for efficient cold chain management to guarantee the stability and effectiveness of these life-saving therapies are obstacles, nevertheless. The UAE's anti-venom sector is nonetheless crucial to the area in spite of these obstacles.


Anti-Venom Market Segments
Type – Market breakup in 2 viewpoints:
1. Polyvalent Anti-Venom
2. Monovalent Anti-Venom


Animal Type – Market breakup in 4 viewpoints:
1. WheatSnake
2. Scorpion
3. Spider
4. Others


End-User – Market breakup in 4 viewpoints:
1. Clinics
2. Hospitals
3. Ambulatory Surgical Centers
4. Others


Country – Market breakup of 25 Countries:
1. North America

1.1 United States
1.2 Canada

2. Europe

2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherlands
2.8 Turkey

3. Asia Pacific

3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Thailand
3.6 Malaysia
3.7 Indonesia
3.8 Australia
3.9 New Zealand

4. Latin America

4.1 Brazil
4.2 Mexico
4.3 Argentina

5. Middle East & Africa

5.1 Saudi Arabia
5.2 UAE
5.3 South Africa


All the Key players have been covered from 3 Viewpoints:
• Overview
• Recent Development
• Revenue Analysis


Company Analysis:
1. Bharat Serums and Vaccines Limited (BSV)
2. Boehringer Ingelheim International GmbH
3. Boston Scientific Corporation
4. CSL Limited
5. Merck & Co. Inc.
6. Merck KGaA
7. Pfizer Inc.
8. Haffkine Bio-Pharmaceutical Corporation Limited


Key Questions Answered in Report:
1. How big is the Anti-Venom industry?
The global Anti-Venom market size was valued at US$ 1.18 billion in 2024 and is expected to reach US$ 2.07 billion in 2033.

2. What is the Anti-Venom growth rate?
The global Anti-Venom market is expected to expand at a compound annual growth rate (CAGR) of 6.50% from 2025 to 2033.

3. Who are the key players in Anti-Venom industry?
Some key players operating in the Anti-Venom market includes Bharat Serums and Vaccines Limited (BSV), Boehringer Ingelheim International GmbH, Boston Scientific Corporation, CSL Limited, Merck & Co. Inc., Merck KGaA, Pfizer Inc., and Haffkine Bio-Pharmaceutical Corporation Limited.

4. What are the factors driving the Anti-Venom industry?
Increased snakebite incidents, increased knowledge of poisonous species, scientific breakthroughs, government health programs, the need for efficient treatments in remote regions, and the expanding need for life-saving therapies are some of the major reasons propelling the anti-venom sector.

5. Which Region held the largest market share in the Anti-Venom industry?
Asia Pacific is expected to hold the largest market share in the industry.

6. What segments are covered in the Anti-Venom Market report?
Type, Animal Type, End-User and Countries segment are covered in this report.

ページTOPに戻る

Table of Contents

1. Introduction


2. Research Methodology


3. Executive Summary


4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges


5. Global Anti-Venom Market


6. Market Share
6.1 Type
6.2 Animal Type
6.3 End Users
6.4 Country


7. Type
7.1 Polyvalent Anti-Venom
7.2 Monovalent Anti-Venom


8. Animal Type
8.1 Snake
8.2 Scorpion
8.3 Spider
8.4 Others


9. End Users
9.1 Clinics
9.2 Hospitals
9.3 Ambulatory Surgical Centers
9.4 Others


10. Country
10.1 North America

10.1.1 United States
10.1.2 Canada

10.2 Europe

10.2.1 France
10.2.2 Germany
10.2.3 Italy
10.2.4 Spain
10.2.5 United Kingdom
10.2.6 Belgium
10.2.7 Netherlands
10.2.8 Turkey

10.3 Asia Pacific

10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 South Korea
10.3.5 Thailand
10.3.6 Malaysia
10.3.7 Indonesia
10.3.8 Australia
10.3.9 New Zealand

10.4 Latin America

10.4.1 Brazil
10.4.2 Mexico
10.4.3 Argentina

10.5 Middle East & Africa

10.5.1 Saudi Arabia
10.5.2 UAE
10.5.3 South Africa


11. Porter’s Five Analysis
11.1 Bargaining Power of Buyers
11.2 Bargaining Power of Suppliers
11.3 Degree of Rivalry
11.4 Threat of New Entrants
11.5 Threat of Substitutes


12. SWOT Analysis
12.1 Strength
12.2 Weakness
12.3 Opportunity
12.4 Threat


13. Key Players
13.1 Bharat Serums and Vaccines Limited (BSV)

13.1.1 Overview
13.1.2 Recent Development
13.1.3 Revenue

13.2 Boehringer Ingelheim International GmbH

13.2.1 Overview
13.2.2 Recent Development
13.2.3 Revenue

13.3 Boston Scientific Corporation

13.3.1 Overview
13.3.2 Recent Development
13.3.3 Revenue

13.4 CSL Limited

13.4.1 Overview
13.4.2 Recent Development
13.4.3 Revenue

13.5 Merck & Co. Inc.

13.5.1 Overview
13.5.2 Recent Development
13.5.3 Revenue

13.6 Merck KGaA

13.6.1 Overview
13.6.2 Recent Development
13.6.3 Revenue

13.7 Pfizer Inc.

13.7.1 Overview
13.7.2 Recent Development
13.7.3 Revenue

13.8 Haffkine Bio-Pharmaceutical Corporation Limited

13.8.1 Overview
13.8.2 Recent Development